Bid/Ask

摘要

Actavis, the largest generic drugmaker in the U.S., will acquire Dublin-based Warner Chilcott in a $5 billion deal that will create an expanded drug portfolio and significant tax advantages. Most employees and executives will remain in the U.S. as headquarters and profits shift to Ireland, a move that will reduce the company's corporate tax burden from 28 percent to 17 percent.